Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemotherapy +/- Radiotherapy for Oligometastatic ES-SCLC
NCT06851819Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in small cell lung cancer (SCLC), sponsored by The Fourth Hospital of Hebei Medical University. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06851819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851819.